Crossmark

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Crossref DOI link: https://doi.org/10.1186/s40425-019-0724-8

Published Online: 2019-09-11

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mullins, Stefanie R. http://orcid.org/0000-0003-4433-2288
Vasilakos, John P.

Deschler, Katharina

Grigsby, Iwen

Gillis, Pete

John, Julius

Elder, Matthew J.

Swales, John

Timosenko, Elina

Cooper, Zachary

Dovedi, Simon J.

Leishman, Andrew J.

Luheshi, Nadia

Elvecrog, James

Tilahun, Ashenafi

Goodwin, Richard

Herbst, Ronald

Tomai, Mark A.

Wilkinson, Robert W.
License Information

Text and Data Mining valid from 2019-09-11
More Information

Article History

Received: 1 April 2019

Accepted: 28 August 2019

First Online: 11 September 2019

Ethics approval and consent to participate

: In vivo experiments were either conducted in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)–accredited and United States Department of Agriculture (USDA)–licensed facility under sterile and standardized environmental conditions, or in accordance with the UK Home Office guidelines, including local ethical review, and the Animals (Scientific Procedure) Act 1986/Directive 2010/63/EU.

: Not applicable

: SRM, KD, SR, MJE, ET, JS, RG, SJD, NL, RH, and RWW are employees of AstraZeneca. JPV, IG, PG, JJ, JE, AT and MT are employees of 3 M.

Document is current

Any future updates will be listed below